Literature DB >> 21916888

Determinants of disability, quality of life and depression in dermatological patients with systemic scleroderma.

H Müller1, P Rehberger, C Günther, J Schmitt.   

Abstract

BACKGROUND: Systemic scleroderma (SSc) is a rare disease and knowledge about the relationship between clinical signs, disability, quality of life and depressive symptoms is still limited. Although patients with SSc are frequently treated by dermatologists, the vast majority of published evidence is based on rheumatological samples.
OBJECTIVES: To identify determinants of disability, decreased quality of life, and depression in a sample of dermatological patients with SSc.
METHODS: This was a cross-sectional study on consecutive patients with SSc attending one specialist dermatological centre between April 2008 and November 2009. Validated questionnaires, the Health Assessment Questionnaire (HAQ), EuroQol (EQ-5D) and the Center for Epidemiologic Studies Depression scale (CES-D) were utilized to measure disability, quality of life and depressive symptoms. Additionally, disease characteristics (SSc subtype, skin thickness, organ involvement), subjective symptoms of SSc, treatment and socioeconomic characteristics were collected by trained investigators. Based on an a priori hypothesized causal model, multivariate logistic regression models were used to analyse determinants of disability, quality of life and depression in patients with SSc.
RESULTS: A total of 72 patients [59 female (82%), mean age 59years] were enrolled. According to the CES-D, 69% (48 out of 70) were screened positive for depression. Quality of life impairment and female sex and were independent risk factors for depressive symptoms. Disease-specific disability was the main determinant of quality of life impairment in SSc. Pain involvement of the musculoskeletal system and male sex were the main determinants of disability in our sample of patients with SSc.
CONCLUSIONS: The high psychosomatic morbidity in our sample of consecutive patients with SSc calls for the investigation of interdisciplinary models of care.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2011        PMID: 21916888     DOI: 10.1111/j.1365-2133.2011.10624.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

Review 1.  Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.

Authors:  Michele Iudici; Serena Fasano; Daniela Iacono; Barbara Russo; Giovanna Cuomo; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2013-11-19       Impact factor: 2.980

Review 2.  Negative affect in systemic sclerosis.

Authors:  Leticia Leon; Lydia Abasolo; Marta Redondo; Miguel Angel Perez-Nieto; Luis Rodriguez-Rodriguez; Maria Isabel Casado; Rafael Curbelo; Juan Angel Jover
Journal:  Rheumatol Int       Date:  2013-09-27       Impact factor: 2.631

Review 3.  Comorbidity burden in systemic sclerosis: beyond disease-specific complications.

Authors:  Eleni Pagkopoulou; Alexandra Arvanitaki; Dimitrios Daoussis; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2019-07-12       Impact factor: 2.631

Review 4.  The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

Authors:  Lesley Ann Saketkoo; Jeanette H Magnus; Mittie K Doyle
Journal:  Am J Med Sci       Date:  2014-01       Impact factor: 2.378

5.  Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools.

Authors:  Gemma Strickland; John Pauling; Charlotte Cavill; Neil McHugh
Journal:  Clin Rheumatol       Date:  2012-05-16       Impact factor: 2.980

6.  Study of depression influencing factors with zero-inflated regression models in a large-scale population survey.

Authors:  Tao Xu; Guangjin Zhu; Shaomei Han
Journal:  BMJ Open       Date:  2017-11-28       Impact factor: 2.692

7.  Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival.

Authors:  DeAnna Baker Frost; Bethany Wolf; Christine Peoples; Jessica Fike; Katherine Silver; Maureen Laffoon; Thomas A Medsger; Carol Feghali-Bostwick
Journal:  Arthritis Res Ther       Date:  2019-04-02       Impact factor: 5.156

8.  Cross-language measurement equivalence of the Center for Epidemiologic Studies Depression (CES-D) scale in systemic sclerosis: a comparison of Canadian and Dutch patients.

Authors:  Linda Kwakkenbos; Erin Arthurs; Frank H J van den Hoogen; Marie Hudson; Wim G J M van Lankveld; Murray Baron; Cornelia H M van den Ende; Brett D Thombs
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

9.  Fatigue Predicts Future Reduced Social Participation, not Reduced Physical Function or Quality of Life in People with Systemic Sclerosis.

Authors:  Susan L Murphy; Daniel Whibley; Anna L Kratz; Janet L Poole; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2020-09-20

10.  An assessment of the measurement equivalence of English and French versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in systemic sclerosis.

Authors:  Vanessa C Delisle; Linda Kwakkenbos; Marie Hudson; Murray Baron; Brett D Thombs
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.